The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | The role of DLL3-directed agents in treating SCLC
Ticiana Leal, MD, Winship Cancer Institute, Atlanta, GA, discusses the use of DLL3-directed agents for treating small cell lung cancer (SCLC). DLL3 is expressed in up to 85% of SCLC and extra-pulmonary SCLC cases. Current studies, in different phases of development, are using T-cell engagers to target DLL3. The Phase I DeLLphi-300 study (NCT03319940) evaluated the use of tarlatamab on heavily patients with pre-treated SCLC. The results demonstrated a promising response rate and overall survival, as well as a strong safety profile with low rates of discontinuation due to adverse events, most of which were grade I and II reversible cytokine response syndrome (CRS). The Phase II DeLLphi-301 study (NCT05060016) showed good responses at a dosage of 10 milligrams. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
